Drug Profile
Research programme: interleukin-4 therapeutics - Medicenna Therapeutics
Alternative Names: IL4-ECs; IL4-Empowered Cytokines; Interleukin-4 Empowered Cytokines™; MDNA 56; MDNA-57Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Medicenna Therapeutics
- Class Antineoplastics; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Haematological-malignancies in USA
- 28 Oct 2020 No recent reports of development identified for research development in Solid-tumours in USA
- 25 Jul 2018 Medicenna has patents pending for Superkine and Empowered Cytokine™ platforms in USA, Canada, European Union, and Asia